Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
Palvella Therapeutics, a clinical-stage biopharmaceutical company specializing in rare skin diseases and vascular malformations, announced the appointment of John D. Doux, M.D., M.B.A., a recognized dermatologist and investor in rare skin disease therapies, to its Board of Directors. Dr. Doux's deep medical experience and previous advocacy for inno…